# Sequestration and Microvascular Congestion Are Associated With Coma in Human Cerebral Malaria

## Mark J. Ponsford,<sup>1</sup> Isabelle M. Medana,<sup>1</sup> Panote Prapansilp,<sup>1,3,5</sup> Tran Tinh Hien,<sup>6</sup> Sue J. Lee,<sup>4</sup> Arjen M. Dondorp,<sup>3,4</sup> Margaret M. Esiri,<sup>2</sup> Nicholas P. J. Day,<sup>3,4</sup> Nicholas J. White,<sup>3,4</sup> and Gareth D. H. Turner<sup>3,4,5</sup>

<sup>1</sup>Nuffield Department of Clinical Laboratory Sciences; <sup>2</sup>Department of Neuropathology, and <sup>3</sup>Nuffield Department of Clinical Medicine, The John Radcliffe Hospital, University of Oxford, United Kingdom; <sup>4</sup>Mahidol-Oxford Research Unit, and <sup>5</sup>Department of Tropical Pathology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; and <sup>6</sup>Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

The pathogenesis of coma in severe *Plasmodium falciparum* malaria remains poorly understood. Obstruction of the brain microvasculature because of sequestration of parasitized red blood cells (pRBCs) represents one mechanism that could contribute to coma in cerebral malaria. Quantitative postmortem microscopy of brain sections from Vietnamese adults dying of malaria confirmed that sequestration in the cerebral microvasculature was significantly higher in patients with cerebral malaria (CM; n = 21) than in patients with non-CM (n = 23). Sequestration of pRBCs and CM was also significantly associated with increased microvascular congestion by infected and uninfected erythrocytes. Clinicopathological correlation showed that sequestration and congestion were significantly associated with deeper levels of premortem coma and shorter time to death. Microvascular congestion and sequestration were highly correlated as microscopic findings but were independent predictors of a clinical diagnosis of CM. Increased microvascular congestion accompanies coma in CM, associated with parasite sequestration in the cerebral microvasculature.

Cerebral malaria (CM) is a common clinical presentation and cause of death in adults with severe malaria in many parts of the world. CM causes a diffuse encephalopathy associated with reduced levels of consciousness or coma, often accompanied by seizures [1]. Focal neurological deficits are relatively unusual. CM represents the lethal end of a disease spectrum, because the majority of *Plasmodium falciparum* malaria cases involve either asymptomatic parasitemia or mild clinical disease. The clinical presentation of malaria depends on both host and parasite factors, including age and immunity. In areas where malaria is highly endemic, young children

The Journal of Infectious Diseases 2012;205:663-71

are most at risk of severe disease. Migrant workers, nonimmune travelers, or persons growing up in areas of low seasonal transmission remain vulnerable to severe malaria throughout life. CM causes 15%–20% mortality despite treatment [2] and long-term neurological sequelae or developmental/cognitive impairment in as many as 1 in 4 child survivors [3, 4]. This results in a continued major worldwide burden of mortality and morbidity, despite improved malaria control measures, such as insecticide-treated bed nets and introduction of early diagnosis and treatment with artemesinin combination therapies [5, 6]. The need to understand the pathophysiology of CM is therefore important in the search for adjuvant neuroprotective treatments for coma.

Pathological studies of brain tissue samples from patients dying of severe malaria have reported a range of findings, the most common of which is the sequestration of parasitized red blood cells (pRBCs) in cerebral microvessels in human adults [7–10] and children [11]. Erythrocytes infected with the later trophozoite and schizont stages of the parasite disappear from the peripheral circulation and preferentially localize in

Received 13 November 2010; accepted 4 April 2011; electronically published 29 December 2011.

Correspondence: Gareth D. H. Turner, MA, BM, BCh, DPhil, FRCPath, Mahidol-Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, 3rd Fl, 60th Anniversary Chalermprakiat Building 420/6, Rajvithi Rd, Bangkok, Thailand 10400 (gareth@tropmedres.ac).

<sup>©</sup> The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com DOI: 10.1093/infdis/jir812

microvessels through specific molecular adhesion between parasite-encoded molecules, such as PfEMP-1, on the pRBC surface, and host ligands, such as CD36 or ICAM-1, on vascular endothelium [12, 13]. Sequestration is a pathological hallmark of human malaria, in contrast with the predominantly inflammatory picture seen in the brain microvasculature in murine models of experimental malaria, which lack cyto-adherent pRBC sequestration [14, 15].

Sequestration occurs to a variable degree throughout the microvasculature in different vital organs, and previous quantitative light and electron microscopic studies have confirmed a quantitative association between sequestration and coma, with higher levels of sequestration seen in the cerebral microvasculature in patients dying of CM [7–11]. In the brain, sequestration causes functional and structural changes to cerebral endothelial cells [16, 17], leading to activation and changes in blood-brain barrier permeability and contributing to secondary neuropathological events, including cerebral edema and axonal injury [18].

Cytoadherence to vascular endothelial cells is one of several different adhesion phenotypes demonstrated by *P falciparum*–infected pRBCs, which also bind in rosettes to uninfected red blood cells (uRBCs), host leukocytes, or other pRBCs in platelet-mediated clumps [19]. The formation of aggregates of cells in vitro has been linked with disease severity and may predispose to microvascular obstruction and interference with blood flow [20]. Studies have shown that the rheology of uRBCs in malaria is abnormal [21] and that ring-stage parasites, which lack cy-toadherence phenotype, also preferentially sequester in the brain [9]. We were therefore interested in examining microvascular obstruction in the cerebral microvasculature to determine whether there was a relationship with sequestration or coma.

The role of vascular obstruction in causing coma and death, compared with other pathological processes, such as metabolic changes, inflammation, or edema, remains a subject of controversy. Imaging studies suggest that adult patients with CM show mildly swollen brains [22], although without frank brain stem herniation in the majority of cases. The relative contributions of extravascular edema and intravascular congestion, caused by sequestration or congestion, are unclear. We performed quantitative morphometric and immunohistochemical analysis of postmortem brain specimens from Vietnamese adults with fatal severe malaria, with and without CM, to examine the relationship between parasite sequestration, intravascular congestion, and coma.

## METHODS

#### **Clinical Definitions and Specimen Collection**

Cortical brain samples were obtained from patients who died of severe *P. falciparum* malaria in a large double-blind comparative trial of parenteral artemether vs quinine for the treatment of severe malaria conducted at the Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, during 1991–1996 [23]. Autopsy was performed as quickly as possible (median time to autopsy, 7 hours); the brain was removed whole and preserved in 10% buffered formalin before a formal brain cut within 6 weeks. Samples taken from the cortex, including white and grey matter in the same block, were embedded and processed using standard histological techniques to formalin-fixed, paraffin-embedded blocks. Patients with CM (n = 21) in this study were defined clinically according to the World Health Organization criteria [1], rather than histologically. This means that patients had a Glasgow Coma Score (GCS) <11 (at admission or defined by neurological examination every 4 hours during the course of disease before death), with associated peripheral parasitemia with P. falciparum proven on microscopy of serial blood smears, and exclusion of other causes of unconsciousness, such as status epilepticus, hypoglycemia, or other central nervous system infections. Patients were defined as not having CM (n = 23) when the GCS was not <11 at any stage before death. Some of this group survived for days after admission and had cleared parasitemia from the peripheral blood smear (and on subsequent histological examination from the cerebral microvasculature) at the time of death but died of other complications of disease, such as renal failure or respiratory disease. None of the non-CM patients had coma at admission without peripheral parasitemia; during subsequent postmortem examination, none of the patients in this study had meningitis or other causes of death that may have simulated severe malaria premortem.

Nonmalarial control samples (n = 10) were from patients dying of non-neurological causes and were collected postmortem at the John Radcliffe Hospital, Oxford, United Kingdom, during 1995-2000. Eight control subjects were agematched to the patients with malaria, and 2 control subjects were older patients, although there was no statistically significant difference in the mean age between the control and malaria groups (controls: median age, 37 years; interquartile range [IQR], 30-56 years). Brain samples were collected using autopsy protocols as described elsewhere [10, 24]. Use of postmortem samples from both the malaria autopsy study in Vietnam and control subjects in Oxford was with informed consent of the relatives of the deceased, and all protocols for use of the tissue samples were approved by local and institutional ethical review boards. Clinical details of the malaria and control cases are shown in Table 1.

## Immunohistochemistry

Immunohistochemistry was performed on cortical brain sections (from the frontal, parietal, or occipital lobes) with use of antibodies to glycophorin A as a marker of red blood cells (RBCs; clone JC159) and CD31 (clone JC70A) as a constitutive vascular marker (both gifts from Jackie Cordell, OxFABs, NDCLS, University of Oxford). Paraffin sections were dewaxed

## Table 1. Clinical Details of Patients With Malaria

37     69     M     92 442     8     CM     Sh, Hyp, ARF, An, J       38     63     M     120 576     10     CM     Sh, Hyp, An, PEd       39     22     M     297 421     7     CM     Sh, Hyp, J, PEd       40     63     M     136 653     11     NCM     Sh, ARF, An, J, PEd       41     32     M     11304     15     NCM     Sh, ARF, J       42     45     F     89 553     10     CM     An, J       43     30     M     21 980     7     CM     An, J       44     52     F     7536     8     CM     Sh, Hyp, An       Control Patients     Age (y)     Sex     Neurological History     Additional Clinical History       1     30     M     None     Hemorrhagic pericarditis, splenomegaly, myelodysplasia       2     56     F     Stupor due to depression/schizophrenia     Aspiration; dehydration; bronchopneumonia       3     35     M     None     Extensive severe bur	Patient	Age, y	Sex	Admission Parasite Level, Parasites/µL	Admission GCS	WHO Diagnosis	Other Clinical Complications
3     00     M     552970     3     C/M     J. B. Hype, APF       5     26     M     3140     11     NCM     An, Hyp, APF       6     27     M     1044 886     15     NCM     An, Hyp, APF       7     46     M     122 264     3     C/M     An, Hyp, APF       9     34     M     105 504     5     C/M     SN, Hyp, APF, APF, APF, APF, APF, APF, APF, APF	1	24	Μ	67 824	4	CM	J
4   5   6   CM   An     5   28   M   3140   104   NCM   An     6   27   M   1024866   15   NCM   An, J     7   46   M   21258   5   CM   Sh, PEd, HyperP     9   34   M   365912   15   NCM   An, J     10   44   M   221588   7   CM   Ahr, J, PEd, HyperP     11   40   F   45622   14   NCM   Hyp, AHF, An, J, PEd     12   33   M   121330   14   NCM   AFR, An, J, HyperP     13   44   F   1101228   14   NCM   ARF, An, J, HyperP     14   28   M   121330   14   NCM   ARF, An, J     15   33   M   121330   14   NCM   ARF, An, J     16   28   M   151202   15   NCM   ARF, An, J     17   28   M   15120   NCM   Sh, AFF, An, J     12   16	2	50	F	8290	14	NCM	Sh, J, ARF
5     26     M     1340     11     NCM     Am       6     27     M     1044966     15     NCM     Sh, Hyp, APF, Ap, PEd, HyperP       7     46     M     212264     3     CM     An, J       8     43     M     105 504     5     CM     An, J       9     34     M     005 912     15     NCM     AHF, AN, JPEd, HyperP       10     44     M     221 558     7     CM     AFF, An, J, PEd       12     33     M     1405 680     15     NCM     AHF, An, J, HyperP       13     44     F     15 072     7     CM     Sh, An       14     28     M     64 390     9     CM     Sh, An       14     28     M     16 12 98     14     NCM     Sh, AnF, An, J       16     27     M     16 12 98     14     NCM     Sh, An, J       17     27     M     16 12 98     14     NCM     Sh,	3	30	Μ	529 278	3	CM	J, Sh, PEd, HyperP
6   M   104490   15   NCM   Sh.pp.AR, Ar, PEd, HyperP     8   43   M   105504   5   CM   An, J     9   34   M   005912   15   NCM   ARF, J.PEd, HyperP     10   44   M   221568   7   CM   ARF, J.PEd     11   40   F   45022   14   NCM   HyperP     12   33   M   11406 680   15   NCM   ARF, J.Ped     12   33   M   11406 680   15   NCM   ARF, An, J. HyperP     13   M   11406 680   15   NCM   ARF, An, J. HyperP     14   Z8   M   619 209   11   NCM   ARF, An, J. HyperP     15   28   M   619 209   11   NCM   ARF, An, J.PerP     20   34   M   105 720   8   CM   S1.Hyp, ARF, An, J     21   22   F   200 564   12   NCM   Sh.PAE, HyperP     22   43   M   1193 20   7   CM <t< td=""><td>4</td><td>51</td><td>F</td><td>69 206</td><td>5</td><td>CM</td><td>An, Hyp, ARF</td></t<>	4	51	F	69 206	5	CM	An, Hyp, ARF
7   46   M   212 294   3   CM   An, J     9   34   M   085 912   15   NCM   Sh, PEd, HyperP     9   34   M   221 568   7   CM   ARF, AN, Fed     10   44   M   221 568   7   CM   ARF, AN, J, PEd     12   33   M   140 680   15   NCM   ARF, An, J, HyperP     14   28   M   543 900   9   CM   Sh, ARF, IthyperP     15   33   M   121 300   14   NCM   ARF, An, J   HyperP     16   28   M   615 294   15   NCM   ARF, An, J   HyperP     17   27   M   65 294   15   NCM   ARF   HyperP     18   27   M   161 298   14   NCM   Sh, Hyp, ARF, An, J   HyperP     19   28   M   116 298   14   NCM   Sh, Hyp, ARF, An, J     20   34   M   105 120   1   NCM   Sh, Hyp, ARF, An, J     21	5	26	Μ	3140	11	NCM	An
8   43   M   10554   5   CM   Sh, PEd, HyperP     9   34   M   20554   7   CM   ARF, AN, PEd     11   40   F   4522   14   NCM   ARF, AN, J, PEd     11   40   F   450   630   9   CM   ARF, AN, J, HperP     13   44   F   15072   7   CM   Sh, ARF, An, J   Her     14   28   M   643 300   9   CM   Sh, ARF, An, J   Her     15   33   M   111930   14   NCM   ARF, An, J   Her     16   28   M   619 208   11   NCM   ARF, An, J   Her     17   27   M   116 298   14   NCM   Sh, Hp, ARF, An, J  Her     18   47   M   116 298   14   NCM   Sh, Hp, ARF, An, J   Her     20   28   M   119 202   7   CM   Sh, Hp, ARF, An, J   Her     21   22   M   112 2815   NG   SM	6	27	Μ	1 044 866	15	NCM	Sh, Hyp, ARF, An, PEd, HyperP
9     94     M     900 12     15     NCM     AHF, AP, Pad       10     44     M     221 558     7     CM     AHF, AP, Pad       11     40     F     4222     14     NCM     Hap, AHF, An, J., HyperP       12     33     M     1450 680     15     NCM     Sh, ARF, HyperP       14     28     M     563 800     9     CM     Sh, ARF, HyperP       15     33     M     121 300     14     NCM     Sh, ARF, HyperP       16     28     M     613 208     11     NCM     Sh, ARF, HyperP       17     27     M     55864     15     NCM     Sh, Hyp, ARF, An, J       18     47     M     150 720     8     CM     Sh, Hyp, ARF, An, J       20     34     M     153 70     1     NCM     Sh, Hyp, ARF, An, J       21     2     F     802 55     14     NCM     Sh, Hyp, ARF, J, HyperP       23     36     F     100 351 7<	7	46	Μ	212 264	3	СМ	An, J
10   44   M   2158   7   CM   AFF.J. PEd     11   40   F   450 600   15   NCM   AFF.An.J. HyperP     13   44   F   15072   7   CM   Sh. AFF.An.J. HyperP     13   33   M   121300   14   NCM   Sh. AFF.An.J. HyperP     15   33   M   121300   14   NCM   Sh. AFF.An.J. HyperP     16   28   M   619208   11   NCM   AFF.An.J. HyperP     17   27   M   155284   15   NCM   AFF.An.J. HyperP     18   47   M   1161298   14   NCM   Sh. Hyp. AFF.An.J.     20   28   M   119200   7   CM   Sh. Hyp. AFF.An.J.     21   22   F   6002544   12   NCM   Sh. Hyp. AFF.An.J.     23   4   19200   7   CM   Sh. Hyp. AFF.An.J.     24   54   M   3517   11   NCM   Sh. AFF.An.J.     25   36   F   2101   13 </td <td>8</td> <td>43</td> <td>Μ</td> <td>105 504</td> <td>5</td> <td>CM</td> <td>Sh, PEd, HyperP</td>	8	43	Μ	105 504	5	CM	Sh, PEd, HyperP
11   40   F   4522   14   NCM   Hyp. AFF, An. J. HyperP     12   33   M   1450 680   15   NCM   AFF, An. J. HyperP     13   44   F   15072   7   C.M   Sh, AFF, HyperP     14   28   M   619 208   11   NCM   Sh, AFF, HyperP     15   33   M   121 330   14   NCM   Sh, AFF, An, J.     16   28   M   619 208   11   NCM   AFF, An, J.     17   27   M   55 264   15   NCM   AFF, An, J.     18   247   M   1161 298   14   NCM   Sh, Hyp, AFF, An, J.     20   34   M   150 720   8   CM   Sh, Hyp, AFF, An, J.     21   22   F   802 654   12   NCM   Sh, Hyp, AFF, An, J.     23   24   M   102 152   14   NCM   Sh, AFF, An, J.     24   54   M   311 253   7   CM   Sh, AFF, An, J.     25   58   F	9	34	Μ	805 912	15	NCM	ARF, AN, Ped
12   33   M   1.400 (80)   15   NCM   ARF, An, J, HyperP     13   44   F   15 072   7   CM   Sh, ARF, HyperP     15   33   M   121 330   14   NCM   Sh, ARF, An, J     16   28   M   619 208   11   NCM   ARF, An, J     17   27   M   619 208   11   NCM   ARF, An, J     18   47   M   161 238   14   NCM   Sh, ARF, HyperP     19   28   M   150 720   8   CM   Sh, Hyp, ARF, An, J     21   22   F   802 584   12   NCM   Sh, Hyp, ARF, An, J     23   34   M   1026 152   14   NCM   Sh, ARF, An, J     24   M   1026 152   14   NCM   Sh, ARF, An, J   Period     24   S4   M   3517   11   NCM   Sh, ARF, An, J   Period     25   B6   F   21 101   13   NCM   Sh, ARF, An, J   Period     26   3	10	44	Μ	221 558	7	CM	ARF, J, PEd
13   44   F   15 072   7   CM   Sh, An     14   28   M   546 360   9   CM   Sh, ARF, An, J     15   33   M   121 330   14   NCM   Sh, ARF, An, J     16   28   M   619 208   11   NCM   ARF, An, J     16   27   M   155 284   15   NCM   An     18   47   M   116 286   14   NCM   Sh, AFF, An, J     20   34   M   150 720   8   CM   Sh, Hyp, ARF, An, J     21   22   F   802 584   12   NCM   Sh, Hyp, ARF, An, J     21   24   M   1026 152   14   NCM   Sh, ARF, An, J     25   56   F   21 101   13   NCM   Sh, ARF, An, J     26   36   M   139 324   8   CM   Sh, ARF, An, J     26   36   M   131 324   16   NCM   Sh, ARF, An, J     27   22   M   47 728   14   N	11	40	F	4522	14	NCM	Hyp, ARF, An, J, PEd
14   28   M   543 800   9   CM   Sh, AFF, HyperP     15   33   M   19 308   14   NCM   AFF, An, J     17   27   M   65 764   15   NCM   AFF, An, J. HyperP     17   27   M   165 764   15   NCM   AFF, An, J. HyperP     18   47   M   1161 298   14   NCM   Sh, AFF, HyperP     19   28   M   165 302   8   CM   Sh, Hyp, AFF, An, J     20   34   M   150 720   8   CM   Sh, Hyp, AFF, An, J     21   22   F   802 564   12   NCM   Sh, Hyp, AFF, An, J     23   24   M   1028 152   14   NCM   Sh, AFF, An, J     24   M   1028 152   14   NCM   Sh, AFF, J, PEd     24   M   193 424   8   CM   Sh, Hyp, AFF, J, HyperP     25   M   241 152   15   NCM   Sh, AFF, An, J     26   S   F   76 365   15   NCM	12	33	М	1 450 680	15	NCM	ARF, An, J, HyperP
14   28   M   516   33   M   121   330   14   NCM   Sh, ABF, An, J     15   28   M   619   208   11   NCM   ABF, An, J, HyperP     17   27   M   65   764   15   NCM   ABF, An, J, HyperP     18   47   M   1161   288   CM   Sh, ABF, HyperP     19   28   M   165   34   NCM   Sh, ABF, HyperP     20   34   M   150   28   CM   Sh, Hyp, ABF, An, J     21   22   F   802   284   12   NCM   Sh, Hyp, ABF, An, J     22   24   M   1026   12   14   NCM   Sh, ABF, An, J     23   24   M   1026   12   14   NCM   Sh, ABF, An, J     24   M   1026   7   10   NCM   Sh, ABF, An, J     25   M   133   24   8   CM   Sh, ABF, An, J     26   S   F   76   165   NCM	13	44	F	15 072	7	СМ	
15   33   M   121 330   14   NCM   Sh, AFF, An, J     16   28   M   619 208   11   NCM   ARF, An, J, HyperP     17   27   M   55 564   15   NCM   An     18   47   M   1161 286   14   NCM   Sh, Hyp, AFF, An, J     20   34   M   150 720   8   CM   Sh, Hyp, AFF, An, J     21   22   F   802 584   12   NCM   Sh, Hyp, AFF, An, J     23   M   103 750   7   CM   Sh, Hyp, AFF, J, PEd     24   M   103 152   14   NCM   Sh, AFF, An, J     25   56   F   21 101   13   NCM   Sh, AFF, An, J     26   36   M   193 424   8   CM   Sh, AFF, An, J     26   36   M   193 424   8   CM   Sh, AFF, An, J     27   22   M   412 847   7   CM   Sh, AFF, An, J     30   M   412 847   7   CM   Sh, Hyp, AFF	14	28	М		9	СМ	Sh. ARF. HyperP
16   28   M   619 208   11   NCM   ARF, An, J, HyperP     17   27   M   55 264   15   NCM   An     18   47   M   1161 298   14   NCM   Sn, AFF, HyperP     19   28   M   45 342   8   CM   Sn, Hyp, AFF, An, J     20   34   M   150 720   8   CM   Sn, Hyp, AFF, An, J     21   22   F   802 584   12   NCM   Sn, Hyp, AFF, An, J     23   24   M   1106 152   14   NCM   Sn, JPE, HyperP     24   56   F   21101   13   NCM   Sn, AFF, J, HyperP     25   56   F   21101   13   NCM   Sn, AFF, An, J     26   36   M   112 588   7   CM   Sn, AFF, An, J     27   22   M   411 52   15   NCM   Sn, AFF, An, J     30   M   412 847   7   CM   Sn, AFF, An, J     31   50   F   76 565   15							
17   27   M   85 284   15   NCM   An   An     18   47   M   1161 238   14   NCM   Sh, ARF, HyperP     19   28   M   45 342   8   CM   Sh, Hyp, ARF, An, J     20   34   M   119 220   7   CM   Sh, Hyp, ARF, An, J     21   22   F   802 584   12   NCM   Sh, Hyp, ARF, J, PEd     23   24   M   1026 152   14   NCM   Sh, JRF, An, J     25   56   F   21101   13   NCM   Sh, ARF, J, PEd     26   36   M   193 424   8   CM   Sh, Hyp, ARF, J, PEd     27   22   M   47 728   14   NCM   Sh, ARF, An, J     30   30   M   411 2837   7   CM   Sh, ARF, An, J     31   50   F   76 385   15   NCM   Sh, ARF, An, J     32   36   F   300   6   CM   Sh, Hyp, ARF, An, J     33   22   M							
18   47   M   1 161 288   14   NCM   Sh, ARF, HyperP     19   28   M   43 342   8   CM   Sh, Hyp, ARF, An, J     20   34   M   160 720   8   CM   Sh, Hyp, ARF, An, J     21   22   35   M   119 320   7   CM   Sh, Hyp, ARF, HyperP     22   35   M   110 2015   14   NCM   Sh, JPF, An, J     24   4   M   3517   11   NCM   Sh, APF, An, J     25   56   F   21101   13   NCM   Sh, APF, An, J     26   36   M   193 424   8   CM   Sh, APF, An, J     27   22   M   417 23   14   NCM   Sh, APF, An, J     28   22   M   421 152   15   NCM   Sh, APF, An, J     30   M   412 847   7   CM   Sh, APF, An, J     31   50   F   7300   6   CM   Sh, Hyp, APF, An, J     33   22   M   335 980							//
19   28   M   45 342   8   CM   Sh, Hya, ARF, An, J     20   34   M   150 720   8   CM   Sh, Hya, ARF, An, J     21   22   7   800 Sh, Hya, ARF, An, J   Sh, Hya, ARF, J, PEd     22   35   M   119 320   7   CM   Sh, Hya, ARF, J, PEd     23   24   M   1026 152   14   NCM   Sh, ARF, An, J     24   54   M   3517   11   NCM   Sh, ARF, An, J     25   56   F   21 101   13   NCM   Sh, ARF, An, J     26   36   M   193 424   8   CM   Sh, ARF, An, J     27   22   M   47 728   14   NCM   Sh, ARF, An, J     28   32   M   241 152   15   NCM   Sh, ARF, An, J     31   50   F   73 685   15   NCM   Sh, ARF, An, J     32   36   F   300   6   CM   Sh, Hya, ARF, An, J     33   22   M   788421   11							
20   34   M   150 720   8   CM   Sh, Hyp, ARF, An, J     21   22   35   M   113 320   7   CM   Sh, Hyp, ARF, Jy PEd     23   24   M   1026 152   14   NCM   Sh, Hyp, ARF, Jy PEd     24   54   M   3517   11   NCM   Sh, ARF, An, J     25   56   F   21101   13   NCM   Sh, ARF, An, J     26   36   M   1193 424   8   CM   Sh, ARF, An, J     27   22   M   417 28   7   CM   Sh, ARF, An, J     28   22   M   477 28   14   NCM   Sh, ARF, An, J     30   30   M   142 847   7   CM   Sh, ARF, An, J     31   50   F   7806   15   NCM   Sh, ARF, An, J     33   22   M   786 21   11   NCM   Sh, Hyp, ARF, An, J     36   F   300   6   CM   Sh, Hyp, ARF, An, J   Sh     36   M   120 576							
21   22   F   802 584   12   NCM   Sh, Hyp, ARF, HyperP     22   35   M   119 320   7   CM   Sh, Hyp, ARF, J, PEd     23   24   M   1025 152   14   NCM   Sh, Hyp, ARF, J, PEd     24   54   M   3517   11   NCM   Sh, ARF, J, PEd     25   56   F   21101   13   NCM   Sh, ARF, J, PEd     26   36   M   193 424   8   CM   Sh, ARF, J, PEd     27   22   M   47 728   14   NCM   Sh, ARF, An, J     30   30   M   4112 847   7   CM   Sh, ARF, An, J     31   50   F   76 655   15   NCM   Sh, ARF, An, J     33   22   M   768 421   11   NCM   Sh, Hyp, ARF, An, J     34   25   M   368 980   15   NCM   Sh, Hyp, ARF, An, J     35   25   M   33890   15   NCM   Sh, Hyp, ARF, An, J     36   34   F							
22   36   M   119 320   7   CM   Sh, Hyp, ARF, J, PEd     23   24   M   1025 152   14   NCM   Sh, J. PEd, HyperP     24   56   F   21 101   13   NCM   Sh, ARF, An, J     26   56   F   21 101   13   NCM   Sh, ARF, J, PEd     26   36   M   193 424   8   CM   Sh, ARF, J, PEd     27   22   M   117 258   7   CM   Sh, ARF, J, PEd     28   22   M   47 728   14   NCM   Sh, ARF, An, J     29   32   M   241 152   15   NCM   Sh, ARF, An, J     30   30   M   412 847   7   CM   Sh, ARF, An, J     31   50   F   76 365   15   NCM   Sh, ARF, An, J     33   22   M   768 421   11   NCM   Sh, Hyp, ARF, An, J     36   43   F   567 712   15   NCM   Hyp, ARF, An, J     36   43   F   567 712 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
23     24     M     1026 152     14     NCM     Sh,J, PEd, HyperP       24     54     M     3617     11     NCM     Sh, ARF, J, PEd       26     36     M     193 424     8     CM     Sh, Hyp, ARF, J, PEd       27     22     M     112 558     7     CM     Sh, ARF, An, J       28     22     M     47 728     14     NCM     Sh, ARF, An, J       29     32     M     241 152     15     NCM     Sh, ARF, An, J       30     30     M     412 847     7     CM     Sh, ARF, An, J       31     50     F     76 365     15     NCM     Sh, ARF, An, J       32     36     F     300     6     CM     Sh, Hyp, ARF, An, J       33     22     M     768 421     11     NCM     Sh, ARF, An, J       36     25     M     305     16     NCM     Hyp, ARF, An, J       36     22     M     32424     8							
24   54   M   3517   11   NCM   Sh, ARF, An, J     25   56   F   21 101   13   NCM   Sh, ARF, J, PEd     26   36   M   133 424   8   CM   Sh, ARF, J, PEd     27   22   M   112 538   7   CM   Sh, ARF, An, J     28   22   M   47 728   14   NCM   Sh, ARF, An, J     30   30   M   412 847   7   CM   Sh, ARF, An, J     31   50   F   76 365   15   NCM   Sh, ARF, An, J     32   36   F   3000   6   CM   Sh, ARF, An, J     33   22   M   768 421   11   NCM   Sh, ARF, An, J     34   25   M   335 980   15   NCM   Sh, Hyp, ARF, An, J     36   43   F   567 712   15   NCM   Sh, Hyp, ARF, An, J     38   63   M   120 576   10   CM   Sh, ARF, An, J, PEd     41   32   M   11 304							
25   56   F   21 101   13   NCM   Sh, ARF, J, PEd     26   36   M   193 424   8   CM   Sh, ARF, J, PEd     27   22   M   112 538   7   CM   Sh, ARF, J, PEd     28   22   M   47 728   14   NCM   Sh, ARF, An, J     29   32   M   241 152   15   NCM   Sh, ARF, An, J     30   M   412 847   7   CM   Sh, ARF, An, J     31   50   F   76 365   15   NCM   Sh, HY, ARF, An, J     33   22   M   768 421   11   NCM   Sh, HY, ARF, An, J     34   25   M   335 980   15   NCM   Sh, Hyp, ARF, An, J     36   43   F   567 712   15   NCM   Sh, Hyp, ARF, An, J     37   69   M   92 442   8   CM   Sh, Hyp, ARF, An, J     38   63   M   120 576   10   CM   Sh, Hyp, ARF, An, J     41   32   M   136 653							
26   36   M   193 424   8   CM   Sh, Hyp, ARF, J, HyperP     27   22   M   112 538   7   CM   Sh, ARF, An, J     28   22   M   47 728   14   NCM   Sh, ARF, An, J     30   30   M   411 52   15   NCM   Sh, ARF, An, J     30   30   M   412 847   7   CM   Sh, ARF, An, J     31   50   F   76 365   15   NCM   Sh, Hyp, ARF, An, J     32   36   F   300   6   CM   Sh, Hyp, ARF, An, J     34   25   M   768 421   11   NCM   Sh, Hyp, ARF, An, J     35   25   M   335 960   15   NCM   Sh, Hyp, ARF, An, J PEd, HyperP     36   43   F   567 712   15   NCM   Sh, Hyp, ARF, An, J PEd, HyperP     37   69   M   92 442   8   CM   Sh, Hyp, AN, F, An, J     38   63   M   120 576   10   CM   Sh, Hyp, AN     40   63							
27   22   M   112 538   7   CM   Sh, ARF, J, PEd     28   22   M   47 728   14   NCM   Sh, ARF, An, J     29   32   M   241 152   15   NCM   Sh, ARF, An, J     30   30   M   412 847   7   CM   Sh, ARF, An, J     31   50   F   76 365   15   NCM   Sh, ARF, An, J     32   36   F   300   6   CM   Sh, Hyp, ARF, An, J     32   36   F   300   6   CM   Sh, Hyp, ARF, An, J     33   22   M   768 421   11   NCM   Sh, Hyp, ARF, An, J     34   25   M   335 980   15   NCM   Hyp, ARF, An, J     36   43   F   567 712   15   NCM   Sh, Hyp, ARF, An, J     38   63   M   120 576   10   CM   Sh, Hyp, ARF, An, J     39   22   M   297 421   7   CM   Sh, HYp, ARF, An, J     41   32   M   11 304<							
28     22     M     47 728     14     NCM     Sn, ARF, An, J       29     32     M     241 152     15     NCM     Sh, ARF, An, J       30     30     M     412 847     7     CM     Sh, ARF, An, J       31     50     F     76 365     15     NCM     Sh, ARF, An, J       32     36     F     300     6     CM     Sh, ARF, An, J       33     22     M     768 421     11     NCM     Sh, ARF, An, J       34     25     M     335 980     15     NCM     Sh, Hyp, ARF, An, J       36     43     F     567 712     15     NCM     Sh, Hyp, ARF, An, J       38     63     M     120 576     10     CM     Sh, Hyp, ARF, An, J       39     22     M     297 421     7     CM     Sh, ARF, J       41     32     M     11304     15     NCM     Sh, ARF, J       42     45     F     89553     10							
29     32     M     241 152     15     NCM     Sh, ARF, An, J       30     30     M     412 847     7     CM     Sh, ARF, An, J       31     50     F     76 365     15     NCM     Sh, ARF, An, J       32     36     F     300     6     CM     Sh, Pry, ARF, An, J       33     22     M     768 421     11     NCM     Sh, ARF, An, J       34     25     M     480     15     NCM     Sh, Hyp, ARF, An, J       35     25     M     335 990     15     NCM     Sh, Hyp, ARF, An, J       36     43     F     567 712     15     NCM     Sh, Hyp, ARF, An, J       36     63     M     120 576     10     CM     Sh, Hyp, ARF, An, J       39     22     M     136 653     11     NCM     Sh, ARF, An, J       40     63     M     136 653     11     NCM     Sh, ARF, An, J       42     45     F     89 553							
30   30   M   412 847   7   CM   Sh, ARF, An, J     31   50   F   76 365   15   NCM   Sh, ARF, An, J     32   36   F   300   6   CM   Sh, Hyp, ARF, An, J     33   22   M   768 421   11   NCM   Sh, ARF, An, J     34   25   M   480   15   NCM   Sh, Hyp, ARF, An, J     36   43   F   567 712   15   NCM   Sh, Hyp, ARF, An, J     36   43   F   567 712   15   NCM   Sh, Hyp, ARF, An, J     38   63   M   120 576   10   CM   Sh, Hyp, ARF, An, J     39   22   M   297 421   7   CM   Sh, Hyp, ARF, An, J, PEd     41   32   M   11304   15   NCM   Sh, AFF, Jan, J, PEd     42   45   F   89 553   10   CM   Sh, Jat     43   30   M   21 980   7   CM   An, J     44   52   F   7536				47 728		NCM	Sh, ARF, An, J
31     50     F     76 365     15     NCM     Sh, ARF, An, J       32     36     F     300     6     CM     Sh, Hyp, ARF, An, J       33     22     M     766 421     11     NCM     Sh, ARF, An, J, HyperP       34     25     M     480     15     NCM     Sh, ARF, An, J       35     25     M     335 980     15     NCM     Sh, PAP, ARF, An, J       36     43     F     567 712     15     NCM     Sh, Hyp, ARF, An, J       38     63     M     120 576     10     CM     Sh, Hyp, ARF, An, J       39     22     M     297 421     7     CM     Sh, Hyp, J, PEd       40     63     M     136 653     11     NCM     Sh, ARF, An, J, PEd       41     32     M     11 304     15     NCM     Sh, ARF, An, J, PEd       42     45     F     89 553     10     CM     Sh, J       43     30     M     21 980	29	32	Μ	241 152	15	NCM	Sh, ARF, An, J
32   36   F   300   6   CM   Sh, Hyp, ARF, An, J     33   22   M   768 421   11   NCM   Sh, ARF, An, J, HyperP     34   25   M   480   15   NCM   Sh, Hyp, ARF, An, J     35   25   M   335 980   15   NCM   Hyp, ARF, An, J     36   43   F   567 712   15   NCM   Sh, Hyp, ARF, An, J     37   69   M   92 442   8   CM   Sh, Hyp, ARF, An, J     38   63   M   120 576   10   CM   Sh, Hyp, ARF, An, J     39   22   M   297 421   7   CM   Sh, Hyp, ARF, An, J     40   63   M   136 653   11   NCM   Sh, ARF, An, J, PEd     41   32   M   11 304   15   NCM   Sh, Hyp, AR     42   45   F   89 553   10   CM   Sh, Hyp, AR     44   52   F   7536   8   CM   Sh, Hyp, AR     7   M   None   Additi	30			412 847	7	CM	Sh, ARF, An, J
33   22   M   768 421   11   NCM   Sh, ARF, An, J, HyperP     34   25   M   480   15   NCM   Sh, Hyp, ARF, An, J     35   25   M   335 980   15   NCM   Hyp, ARF, An, J     36   43   F   567 712   15   NCM   Sh, Hyp, ARF, An, J, PEd, HyperF     37   69   M   92 442   8   CM   Sh, Hyp, ARF, An, J     38   63   M   120 576   10   CM   Sh, Hyp, ARF, An, J, PEd     39   22   M   297 421   7   CM   Sh, Hyp, ARF, An, J, PEd     40   63   M   136 653   11   NCM   Sh, ARF, An, J, PEd     41   32   M   11304   15   NCM   Sh, J     42   45   F   89 553   10   CM   Sh, J     43   30   M   21 980   7   CM   An, J     44   52   F   7536   8   CM   Sh, Hyp, ARF     7   30   M   None <td>31</td> <td>50</td> <td>F</td> <td>76 365</td> <td>15</td> <td>NCM</td> <td>Sh, ARF, An, J</td>	31	50	F	76 365	15	NCM	Sh, ARF, An, J
34   25   M   480   15   NCM   Sh, Hyp, ARF, An, J     35   25   M   335 980   15   NCM   Hyp, ARF, An, J     36   43   F   567 712   15   NCM   Sh, Hyp, ARF, An, J     37   69   M   92 442   8   CM   Sh, Hyp, ARF, An, J     38   63   M   120 576   10   CM   Sh, Hyp, ARF, An, J     39   22   M   297 421   7   CM   Sh, Hyp, ARF, An, J     40   63   M   136 653   11   NCM   Sh, ARF, An, J     41   32   M   11 304   15   NCM   Sh, J     42   45   F   89 553   10   CM   Sh, J     43   30   M   21 980   7   CM   An, J     44   52   F   7536   8   CM   Sh, Hyp, An     Control Patients   Age (y)   Sex   Neurological History   Additional Clinical History     1   30   M   None   Extensive seve	32	36	F	300	6	CM	Sh, Hyp, ARF, An, J
35   25   M   335 980   15   NCM   Hyp, ARF, An, J     36   43   F   567 712   15   NCM   Sh, Hyp, ARF, An, J, PEd, Hyperi     37   69   M   92 442   8   CM   Sh, Hyp, ARF, An, J     38   63   M   120 576   10   CM   Sh, Hyp, ARF, An, J     39   22   M   297 421   7   CM   Sh, Hyp, JPEd     40   63   M   136 653   11   NCM   Sh, ARF, An, J, PEd     41   32   M   11 304   15   NCM   Sh, ARF, J     42   45   F   89 553   10   CM   Sh, J     43   30   M   21 980   7   CM   An, J     44   52   F   7536   8   CM   Sh, Hyp, An     Control Patients   Age (y)   Sex   Neurological History   Additional Clinical History     1   30   M   None   Extensive severe burns of the skin; smoke inhalation     4   35   M   None   E	33	22	Μ	768 421	11	NCM	Sh, ARF, An, J, HyperP
36   43   F   567 712   15   NCM   Sh, Hyp, ARF, An, J, PEd, Hyperf     37   69   M   92 442   8   CM   Sh, Hyp, ARF, An, J     38   63   M   120 576   10   CM   Sh, Hyp, ARF, An, J     39   22   M   297 421   7   CM   Sh, Hyp, J, PEd     40   63   M   136 653   11   NCM   Sh, ARF, An, J, PEd     41   32   M   11304   15   NCM   Sh, ARF, J     42   45   F   89 553   10   CM   Sh, J     43   30   M   21 980   7   CM   An, J     44   52   F   7536   8   CM   Sh, Hyp, An     20   Age (y)   Sex   Neurological History   Additional Clinical History     1   30   M   None   Hemorrhagic pericarditis, splenomegaly, myelodysplasia     2   56   F   Stupor due to depression/schizophrenia   Aspiration; dehydration; bronchopneumonia     3   35   M   None	34	25	Μ	480	15	NCM	Sh, Hyp, ARF, An, J
37     69     M     92 442     8     CM     Sh, Hyp, ARF, An, J       38     63     M     120 576     10     CM     Sh, Hyp, An, PEd       39     22     M     297 421     7     CM     Sh, Hyp, An, J, PEd       40     63     M     136 653     11     NCM     Sh, ARF, An, J, PEd       41     32     M     11304     15     NCM     Sh, ARF, J       42     45     F     89 553     10     CM     Sh, J       43     30     M     21 980     7     CM     An, J       44     52     F     7536     8     CM     Sh, Hyp, An       Control Patients     Age (y)     Sex     Neurological History     Additional Clinical History       1     30     M     None     Hemorrhagic pericarditis, splenomegaly, myelodysplasia       2     56     F     Stupor due to depression/schizophrenia     Aspiration; dehydration; bronchopneumonia       3     35     M     None     Extensive severe	35	25	Μ	335 980	15	NCM	Hyp, ARF, An, J
38   63   M   120 576   10   CM   Sh, Hyp, An, PEd     39   22   M   297 421   7   CM   Sh, Hyp, J, PEd     40   63   M   136 653   11   NCM   Sh, ARF, An, J, PEd     41   32   M   11 304   15   NCM   Sh, ARF, J     42   45   F   89 553   10   CM   Sh, J     43   30   M   21 980   7   CM   An, J     44   52   F   7536   8   CM   Sh, Hyp, An     Control Patients   Age (y)   Sex   Neurological History   Additional Clinical History     1   30   M   None   Hemorrhagic pericartitis, splenomegaly, myelodysplasia     2   56   F   Stupor due to depression/schizophrenia   Aspiration; dehydration; bronchopneumonia     3   35   M   None   Extensive severe burns of the skin; smoke inhalation     4   35   M   Epilepsy; previous encephalitis   PEd     5   27   M   Unconscious, right-sided focal   PEd	36	43	F	567 712	15	NCM	Sh, Hyp, ARF, An, J, PEd, HyperP
3922M297 4217CMSh, Hyp, J, PEd4063M136 65311NCMSh, ARF, An, J, PEd4132M11 30415NCMSh, ARF, J4245F89 55310CMSh, J4330M21 9807CMAn, J4452F75368CMSh, Hyp, AnControl PatientsAge (y)SexNeurological HistoryAdditional Clinical History130MNoneHemorrhagic pericarditis, splenomegaly, myelodysplasia256FStupor due to depression/schizophreniaAspiration; dehydration; bronchopneumonia335MEpilepsy; previous encephalitisPEd527MUnconscious, right-sided focalPEd; anorexia nervosa; Hyp623FNoneSickle cell trait; severe hemorrhage745MNoneSplenomegaly839FNoneChronic renal failure; gastric bleed995FNoneHepatocellular carcinoma	37	69	Μ	92 442	8	CM	Sh, Hyp, ARF, An, J
4063M136 65311NCMSh, ARF, An, J, PEd4132M11 30415NCMSh, ARF, J4245F89 55310CMSh, J4330M21 9807CMAn, J4452F75368CMSh, Hyp, AnControl PatientsAge (y)SexNeurological HistoryAdditional Clinical History130MNoneHemorrhagic pericarditis, splenomegaly, myelodysplasia256FStupor due to depression/schizophreniaAspiration; dehydration; bronchopneumonia335MNoneExtensive severe burns of the skin; smoke inhalation435MEpilepsy; previous encephalitisPEd527MUnconscious, right-sided focalPEd; anorexia nervosa; Hyp623FNoneSickle cell trait; severe hemorrhage745MNoneSplenomegaly839FNoneChronic renal failure; gastric bleed995FNoneHepatocellular carcinoma	38	63	М	120 576	10	СМ	Sh, Hyp, An, PEd
4132M11 30415NCMSh, ARF, J4245F89 55310CMSh, J4330M21 9807CMAn, J4452F75368CMSh, Hyp, AnControl PatientsAge (y)SexNeurological HistoryAdditional Clinical History130MNoneHemorrhagic pericarditis, splenomegaly, myelodysplasia256FStupor due to depression/schizophreniaAspiration; dehydration; bronchopneumonia335MNoneExtensive severe burns of the skin; smoke inhalation435MEpilepsy; previous encephalitisPEd527MUnconscious, right-sided focalPEd; anorexia nervosa; Hyp623FNoneSplenomegaly745MNoneSplenomegaly839FNoneChronic renal failure; gastric bleed995FNoneHepatocellular carcinoma	39	22	Μ	297 421	7	СМ	Sh, Hyp, J, PEd
4245F89 55310CMSh, J4330M21 9807CMAn, J4452F75368CMSh, Hyp, An4452F75368CMSh, Hyp, AnControl PatientsAge (y)SexNeurological HistoryAdditional Clinical History130MNoneHemorrhagic pericarditis, splenomegaly, myelodysplasia256FStupor due to depression/schizophreniaAspiration; dehydration; bronchopneumonia335MNoneExtensive severe burns of the skin; smoke inhalation435MEpilepsy; previous encephalitisPEd527MUnconscious, right-sided focalPEd; anorexia nervosa; Hyp623FNoneSickle cell trait; severe hemorrhage745MNoneSplenomegaly839FNoneChronic renal failure; gastric bleed995FNoneHepatocellular carcinoma	40	63	М	136 653	11	NCM	Sh, ARF, An, J, PEd
4245F89 55310CMSh, J4330M21 9807CMAn, J4452F75368CMSh, Hyp, An4452F75368CMSh, Hyp, AnControl PatientsAge (y)SexNeurological HistoryAdditional Clinical History130MNoneHemorrhagic pericarditis, splenomegaly, myelodysplasia256FStupor due to depression/schizophreniaAspiration; dehydration; bronchopneumonia335MNoneExtensive severe burns of the skin; smoke inhalation435MEpilepsy; previous encephalitisPEd527MUnconscious, right-sided focalPEd; anorexia nervosa; Hyp623FNoneSickle cell trait; severe hemorrhage745MNoneSplenomegaly839FNoneChronic renal failure; gastric bleed995FNoneHepatocellular carcinoma							
4330M21 9807CMAn, J4452F75368CMSh, Hyp, AnControl PatientsAge (y)SexNeurological HistoryAdditional Clinical History130MNoneHemorrhagic pericarditis, splenomegaly, myelodysplasia256FStupor due to depression/schizophreniaAspiration; dehydration; bronchopneumonia335MNoneExtensive severe burns of the skin; smoke inhalation435MEpilepsy; previous encephalitisPEd527MUnconscious, right-sided focalPEd; anorexia nervosa; Hyp623FNoneSickle cell trait; severe hemorrhage745MNoneSplenomegaly839FNoneChronic renal failure; gastric bleed995FNoneHepatocellular carcinoma							
4452F75368CMSh, Hyp, AnControl PatientsAge (y)SexNeurological HistoryAdditional Clinical History130MNoneHemorrhagic pericarditis, splenomegaly, myelodysplasia256FStupor due to depression/schizophreniaAspiration; dehydration; bronchopneumonia335MNoneExtensive severe burns of the skin; smoke inhalation435MEpilepsy; previous encephalitisPEd527MUnconscious, right-sided focalPEd; anorexia nervosa; Hyp623FNoneSickle cell trait; severe hemorrhage745MNoneSplenomegaly839FNoneChronic renal failure; gastric bleed995FNoneHepatocellular carcinoma							
130MNoneHemorrhagic pericarditis, splenomegaly, myelodysplasia256FStupor due to depression/schizophreniaAspiration; dehydration; bronchopneumonia335MNoneExtensive severe burns of the skin; smoke inhalation435MEpilepsy; previous encephalitisPEd527MUnconscious, right-sided focalPEd; anorexia nervosa; Hyp623FNoneSickle cell trait; severe hemorrhage745MNoneSplenomegaly839FNoneChronic renal failure; gastric bleed995FNoneHepatocellular carcinoma							
256FStupor due to depression/schizophreniaAspiration; dehydration; bronchopneumonia335MNoneExtensive severe burns of the skin; smoke inhalation435MEpilepsy; previous encephalitisPEd527MUnconscious, right-sided focalPEd; anorexia nervosa; Hyp623FNoneSickle cell trait; severe hemorrhage745MNoneSplenomegaly839FNoneChronic renal failure; gastric bleed995FNoneHepatocellular carcinoma	Control Patients	Age (y)	Sex	Neurological Hist	ory	Ad	ditional Clinical History
335MNoneExtensive severe burns of the skin; smoke inhalation435MEpilepsy; previous encephalitisPEd527MUnconscious, right-sided focalPEd; anorexia nervosa; Hyp623FNoneSickle cell trait; severe hemorrhage745MNoneSplenomegaly839FNoneChronic renal failure; gastric bleed995FNoneHepatocellular carcinoma	1	30	Μ	None		Hemorrhagic per	icarditis, splenomegaly, myelodysplasia
435MEpilepsy; previous encephalitisPEd527MUnconscious, right-sided focalPEd; anorexia nervosa; Hyp623FNoneSickle cell trait; severe hemorrhage745MNoneSplenomegaly839FNoneChronic renal failure; gastric bleed995FNoneHepatocellular carcinoma	2	56	F	Stupor due to depression/sc	hizophrenia	Aspiration; dehy	dration; bronchopneumonia
527MUnconscious, right-sided focalPEd; anorexia nervosa; Hyp623FNoneSickle cell trait; severe hemorrhage745MNoneSplenomegaly839FNoneChronic renal failure; gastric bleed995FNoneHepatocellular carcinoma	3	35	Μ	None		Extensive severe	e burns of the skin; smoke inhalation
527MUnconscious, right-sided focalPEd; anorexia nervosa; Hyp623FNoneSickle cell trait; severe hemorrhage745MNoneSplenomegaly839FNoneChronic renal failure; gastric bleed995FNoneHepatocellular carcinoma	4	35	М	Epilepsy; previous encephali	tis	PEd	
623FNoneSickle cell trait; severe hemorrhage745MNoneSplenomegaly839FNoneChronic renal failure; gastric bleed995FNoneHepatocellular carcinoma							ervosa; Hyp
745MNoneSplenomegaly839FNoneChronic renal failure; gastric bleed995FNoneHepatocellular carcinoma						•	
8 39 F None Chronic renal failure; gastric bleed   9 95 F None Hepatocellular carcinoma							
9 95 F None Hepatocellular carcinoma							lure: gastric bleed
							· •
10 86 M None Acute upper GI bleeding and ischemic heart disease	9 10	86	M	None			

Abbreviations: An, anemia; ARF, acute renal failure; CM, cerebral malaria; GCS, Glasgow Coma Score; GI, gastrointestinal; Hyp, hypoglycemia; HyperP, hyperparasitemia; J, jaundice; NCM, non-cerebral malaria; PEd, pulmonary edema; Sh, shock; WHO, World Health Organization.

and rehydrated and then underwent microwave (for glycophorin) or trypsin antigen retrieval (for CD31), according to standard protocols, as described elsewhere [25, 26]. The primary antibodies were incubated for 45 minutes on the section, the slides were washed in Tris buffered saline 3 times for 5 minutes, and incubation was done with biotinylated goat antimouse immuno-globulin for 30 minutes, followed by Streptavidin ABComplex alkaline phosphatase. The chromogen used was the new fuchsin substrate system (all kits and substrates obtained from DAKO). The reaction was observed under a microscope and quenched by washing with Tris buffered saline. Slides were mounted in Aquamount (BDH) and counterstained with hematoxylin. Negative controls comprised sections immunostained using the aforementioned methods, except for omission of the primary antibody.

## Microscopy and Quantitation of Vessels by Image Analysis

Images were captured under  $\times 250$  magnification with use of QImaging software with a Zeiss microscope and analyzed using Adobe Photoshop software. CD31 and glycophorin were used as markers for endothelial cells and the erythrocyte membrane, respectively, on slides of cortical brain. The number of vessels stained with CD31 was quantitated with a graticule to provide a measure of vessels per unit area of cortex (per square millimeter). This was done in total for the section and using separate counts for grey and white matter areas. The individual counts of vessels from 6 separate fields from each case were averaged to produce a vessel density per square millimeter for each case. This single figure was correlated with clinical, biochemical, and histopathological data.

To assess microvascular congestion, the blood vessels examined were defined as small- to medium-sized vessels (2–10 erythrocytes in diameter, representing small arterioles and venules) that contained RBCs on glycophorin immunostaining (Figure 1). Congestion was defined by the presence in a vessel lumen of erythrocytes (both uninfected and infected) staining positively with glycophorin. Congestion was therefore a measure of the number of small vessels containing RBCs in a section.

Sequestration was defined morphologically as the presence of pRBCs in a vessel. Both uRBCs and pRBCs stained for glycophorin; thus, the presence of malaria pigment in RBCs or the presence of a visible parasite nucleus was used to differentiate between pRBCs and uRBCs. The number of vessels showing either congestion or sequestration was quantitated and calculated as a percentage of the total vessel count (ratio of congested or sequestered vessels to total vessels on CD31 staining).

#### **Statistical Analysis**

All analyses were performed using SPSS, version 17, or Stata, version 11 (StataCorp). Comparisons were made across the 3 groups: CM, non-CM, and controls. Differences between groups were assessed using the Fisher exact test for categorical variables and the Kruskal-Wallis test for continuous variables. Variables

were log-transformed to a normal distribution when possible, but analysis of variance was used for normally distributed continuous variables only if the variances were similar for all groups. To further elucidate the relationship between exposure and outcome, post hoc pairwise comparisons (ie, CM vs non-CM, CM vs controls, and non-CM vs controls) were made only when the initial comparison showed a significant association or when data were available for only the 2 severe malaria groups. Student t test or Mann–Whitney U test was used to assess pairwise comparisons, as appropriate. Correlations for continuous variables among patients with malaria were tested using Spearman rank correlation coefficient.


To quantify the risk associated with clinical and neuropathological features that were significant predictors of cerebral malaria, logistic regression modeling was used. Cerebral malaria was the dependent variable, and all quantitative measures of neuropathology that were significant in the univariate analysis at P < .05 were included as covariates. The best predictor or combination of predictors was determined using the likelihood ratio test and by checking the area under the receiver-operating characteristic (ROC) curves. Goodness-of-fit for the models was confirmed using the Homer-Lemeshow  $\chi^2$  test.

No adjustment was made for multiple comparisons; however, for *P* values > .001, exact numbers are reported so that a Bonferroni-Dunn correction can be calculated (ie,  $\alpha = .05/k$ , where k = number of tests).

## RESULTS

Patients with CM showed a higher degree of congestion, as measured by the number of congested blood vessels per unit area of the cerebral cortex (median density, 39.7 blood vessels/mm<sup>2</sup>; IQR, 19.8–48.4 blood vessels/mm<sup>2</sup>), compared with non-CM (9.52 blood vessels/mm<sup>2</sup>; IQR, 4.76–20.6 blood vessels/mm<sup>2</sup>; P = .002) and nonmalarial controls (8.73 blood vessels/mm<sup>2</sup>; IQR, 7.14–15.9 blood vessels/mm<sup>2</sup>; P = .007) (Figure 1*D*). There was no statistically significant difference in congestion between controls and patients with non-CM (P = .78), implying that the differences in observed vascularity and microvascular congestion were not simply attributable to postmortem leaching of RBCs from patent vessels.

The difference among patients with CM and other clinical groups remained statistically significant when adjusted for variation in the vessel density between areas of the cortex. Grey matter, which normally has a higher density of vessels than white matter [27, 28], logically showed a higher degree of congested vessels (grey matter to white matter ratio: CM, 1.55 [median, 44.4; IQR, 17.5–68.3 to 28.6; IQR, 12.7–38.1], non-CM, 1 [median, 9.52; IQR, 4.76–30.2 to 9.52; IQR, 3.17–19.1], controls, 1.30 [median, 10.3; IQR, 7.94–14.3 to 7.94; IQR, 3.17–11.1]), although this was only borderline significantly different in cases of cerebral malaria (P = .06).



**Figure 1.** A-C, Images of cortical brain sections from patients with malaria that were stained for glycophorin A. *A*, Low-power image showing noncongested vessels. Examples of vessels without erythrocytes indicated with arrows (magnification  $\times 250$ ; scale bar, 100 µm; counterstained with hematoxylin). *B*, Low-power image showing vessels congested with parasitized and nonparasitized erythrocytes (*arrows*; magnification  $\times 250$ ; scale bar 100 µm; counterstained with hematoxylin). *C*, High-power image of a congested vessel showing both infected and uninfected red blood cells in a congested vessel (scale bar, 100 µm). *D*, Box plots showing a comparison of the number of congested vessels per square millimeter in non–cerebral malaria, cerebral malaria, and control cases. Boxes show median values with interquartile ranges and limiting values.

Sequestration of pRBCs was significantly higher in the cortical brain sections of patients with CM than in patients with non-CM (P = .01) (Table 2 and Figure 2A). The percentage of congested microvessels was strongly positively correlated with percentage of vessels showing sequestration of parasitized erythrocytes (Spearman  $\rho = 0.85$ ; P < .0001) (Figure 2B). Moreover, both sequestration and congestion were inversely associated with time to death after admission to hospital (Spearman  $\rho = -0.61$  and  $\rho = -0.51$ , respectively; both P < .001). The level of consciousness, as measured by the GCS, was also inversely correlated with both parameters (Spearman  $\rho = -0.48$ ; P = .001 for sequestration; Spearman  $\rho = -0.52$ ; P = .0003 for congestion).

The clinical and neuropathological correlates of CM and non-CM were examined (Table 2). There was no difference between the CM and non-CM groups in terms of their age, admission parasitemia, or type of treatment received after admission (either artemether or quinine). Across the malaria groups, drug type was also not associated with a difference in the degree of congestion or sequestration observed microscopically (P = .19and P = 0.61, respectively). No relationship was found between the degree of sequestration or congestion and hematocrit (P = .08 and P = 0.34, respectively), implying that lower rates of congestion or sequestration cannot be explained simply by the presence of anemia.

A number of clinical features were not associated with CM in this series, including shock, anemia, jaundice, hypoglycemia, pulmonary edema, and the incidence of convulsions before admission. Brain weight at autopsy and cerebrospinal fluid

#### Table 2. Statistical Comparison of the Clinical Parameters of Cerebral Malaria and Non-Cerebral Malaria Cases

	CM	Non-CM	P Value
Number of patients	21	23	
Age (years)	36 (22–69)	32 (22–63)	.31
Drug therapy	A = 11, Q = 10	A = 7, Q = 16	.22
Maximum temperature, °C	39.5 (38.3–40)	39.0 (38.3–39.8)	.79
Maximum heart rate, beats/min	120 (120–140)	120 (116–140)	.95
Time to death, h	36.0 (13–56)	44 (18–123.5)	.31
At admission			
Glasgow Coma Score	7 (3–10)	14 (11–15)	.0001
Hemotocrit, %	30 (8–50)	28 (6–47)	.66
Geometric mean (95% CI) parasitemia/µL	80 665 (37 403–173 963)	96 144 (34 836–265 346)	.78
Lactate (plasma), mmol/L	6.7 (2.2–18.3)	3.7 (0.4–1.03)	.03
Creatinine (serum), mg/dL	2.3 (0.7–7.5)	4.4 (1.03–11)	.02
White cell count $ imes$ 10 <sup>-8</sup> , cells/mm <sup>3</sup>	12.8 (3.0–31.5)	11.0 (2.0–36.8)	.30
Platelet count $ imes$ 10 <sup>-4</sup> , cells/mm <sup>3</sup>	32 (20–194)	40 (12–120)	.66
Bilirubin, mg/dL	5.2 (1.0–18.8)	9.9 (0.6–18.0)	.21
CSF opening pressure, /mm H <sub>2</sub> 0	17 (10.5–22); n = 16	14 (13.5–19); n = 5	.90
CSF protein	140 (70–208); n = 18	70 (53–130); n = 6	.04
CSF white cell count	3 (0–6); n = 17	0 (0–2); n = 6	.04
No. (%) with acute renal failure	9 (42.9)	17 (73.9)	.07
No. (%) with jaundice	14 (66.7)	18 (78.3)	.50
No. (%) with shock	8 (34.8)	6 (28.6)	.75
No. (%) with hypoglycemia	2 (9.52)	4 (17.4)	.67
No. (%) with pulmonary edema	1 (4.76)	2 (8.70)	1.0
No. (%) with convulsions	5 (25.0)	1 (4.35)	.08
No. (%) with dialysis	3 (47.8)	11 (14.3)	.02
Histopathological			
Sequestration, %	84.9 (68.8–93.2)	13.7 (0–73.2)	.01
Congestion, vessels/mm <sup>3</sup>	39.7 (19.8–48.1)	9.52 (4.76–20.6)	.002
Brain mass, g	1335 (1240–1400)	1300 (1290–1400)	.95

All values are median (interquartile range), unless otherwise specified. Results in bold show significant differences between CM and Non-CM patient groups, *P* < .05. Abbreviations: A, Artemether; CI, confidence interval; CM, cerebral malaria; CSF, cerebrospinal fluid; Q, Quinine.

(CSF) opening pressure were also not significantly different between the 2 groups.


However, microvascular congestion, sequestration of pRBCs, admission lactate, CSF protein level, and CSF white blood cell count were significantly associated with cerebral malaria with use of the Mann–Whitney *U* test (Table 2). When the risk was quantified using logistic regression, CSF protein level (n = 24; odds ratio [OR], 1.03; 95% confidence interval [CI], .99–1.06) and CSF white blood cell count (n = 23; OR, 1.75; 95% CI, .81–3.79) were no longer significantly associated with CM possibly because of small sample size. Coma score was significantly associated because of the clinical definition of the CM group; risk could not be quantified, because all patients with GCS  $\leq 11$  were considered to have CM.

Acute renal failure, as defined by higher levels of plasma creatinine, were associated with lower risk of CM (OR, 0.71;

95% CI, .52–.97), as was the requirement for treatment by dialysis after admission (OR, 0.18; 95% CI, .04–.79). Higher levels of admission lactate level were borderline significantly associated with higher odds of CM (OR, 1.16; 95% CI, .99–1.36). When assessed using likelihood ratio testing, percentage vessel sequestration was a good independent predictor (OR, 1.02; 95% CI, 1.01–10.4; ROC area, 0.72), but microvascular congestion was the best independent predictor of CM (OR, 1.07; 95% CI, 1.02–1.12; P = .0001; ROC area, 0.77). Multivariate combinations of the aforementioned variables either did not provide a good model fit or did not predict as well as the single covariate models.

## DISCUSSION

Sequestration of *P falciparum*–parasitized erythrocytes in the cerebral microvasculature has been a consistent feature of pathological studies of CM since the seminal studies of Marchiafava



**Figure 2.** *A*, Box plot showing the difference between sequestration in cerebral malaria and non–cerebral malaria cases. This measured the percentage of vessels in cortical brain sections showing sequestration of parasitized red blood cells. Boxes show median values with interquartile ranges and limiting values. *B*, Dot plot showing the correlation between sequestration and microvascular congestion in individual cases.

et al [29] more than a century ago. Because the extent of sequestration is so marked and the microvascular pathology is so distinctive, observers have proposed this as the central pathogenic process causing coma in CM [2, 7, 30, 31]. Previous studies have quantitated the degree of sequestration in cerebral vessels in patients with CM and shown a significant association between premortem coma and cerebral sequestration, using both electron [7, 8, 10] and light microscopy [11, 22] on brain sections or brain smears [9]. This study confirms the significant association between premortem sequestration of malaria-infected erythrocytes in cerebral microvessels and the coma of CM in adults.

Data derived from murine models of experimental CM, in which histological evidence of extensive parasitized RBC sequestration is lacking, have led some authors to suggest that coma and death result from immunopathological processes independent of sequestration [15, 32]. Other studies have reported accumulation of other host cells, such as leukocytes or platelets, predominantly in pediatric African patients with CM [33]. In Southeast Asian adults, our results confirm that histological evidence of cerebral microvascular sequestration with pRBCs is significantly and quantitatively linked to premortem coma. The only other neuropathological correlates that we previously found to be significantly associated with coma in this group is axonal injury [24].

In our study, we revealed a significant increase in the number of patent microvessels in the brain after death due to cerebral malaria, because of congestion of vessels by uninfected and infected RBCs. This phenomenon of microvascular congestion showed a significant correlation with sequestration and coma. These results support the hypothesis that cerebral microvascular obstruction is central to the pathogenesis of coma. Extensive sequestration and congestion was associated with a shorter time to death, a lower level of premortem consciousness, and markers of severe disease, such as a high blood lactate concentration, which is an established prognostic marker of poor outcome in severe malaria [34].

One hypothesis to explain microvascular congestion would be backing up behind downstream obstruction in the capillary or postvenular beds, caused by pRBC sequestration. However, although these 2 features were strongly correlated, congestion proved a better predictor of coma, and other factors may contribute to congestion independently of sequestration. These could include reduced deformability of uRBCs during malaria infection or other adhesive phenotypes, such as rosetting and platelet-mediated clumping of pRBCs. Congestion has a number of important consequences, including impaired tissue perfusion that may cause diffuse cerebral ischemia and an increased intracranial blood volume. Global measurement of intravascular blood volume would be important to assess whether histological evidence of microvascular congestion correlates with increased intravascular volume in CM, as opposed to fluid leakage into the brain parenchyma because of vasogenic edema. Our studies of this group indicate that patterns of perivascular or parenchymal edema are not significantly associated with coma in these patients [35].

Congestion represents opening of small vessels that are not usually patent. Blood flow in the cortex is tightly linked to neuronal energy requirements. An inappropriate dilation and packing of multiple small vessels may have a pathological effect on cortical function, through a disconnection between neuronal metabolism and flow. Coma may represent a potentially neuroprotective response of global decreased neuronal function in the face of inadequate blood supply or metabolic competition from developing intravascular parasites. The unique pathology of CM, with sequestration, cerebral microvascular congestion, and obstruction, and the contribution of changes to uninfected and cytoadherent infected erythrocytes is different from other causes of large vessel hypoxic and/or ischemic damage. Whether coma is a neuroprotective response is an important question, because efforts to reverse it with adjuvant therapies could then risk exacerbating injury, causing reflow damage or contributing to long-term neurological sequelae.

Recent work in the Plasmodium coatneyi primate model of CM (in which there is significant cerebral sequestration) using positron-emission tomography to map glucose use revealed diffuse and heterogeneous reduction of metabolism in the cortex during the acute phase of infection [36], which is consistent with an impaired microcirculation. A functioning microcirculation protects organs from the effects of diminished oxygen and metabolite supply, and impairment of microcirculatory function may cause diminished oxygenation despite normal overall oxygen delivery to an organ [37]. Changes in microcirculatory function has been directly visualized in the buccal and rectal vessels in patients with severe malaria, in which the patterns of obstruction and flow differ from sepsis, a widely used model of the contribution of microcirculatory dysfunction to tissue injury [38]. Our results imply that dysregulation of the control of microcirculatory blood supply occurs in the brain during CM.

Brain swelling in CM is a variable finding in radiological and postmortem studies of adults with fatal malaria [21]. With greater occlusion of cerebral blood flow, increased hydrostatic pressure might lead to hemorrhages and cerebral edema. However, preliminary examination of the incidence of edema, fibrinogen leakage, and microscopic hemorrhages in these patients reveal no association with the degree of sequestration or congestion [35]. Systemic, as opposed to local, microcirculatory factors may also contribute to defects in cerebral blood flow during severe malarial illness. Shock is present in only 12% of cases in both adult [39] and pediatric [40] severe malaria but was seen in a disproportionately high number of the fatal cases in this study, reflecting the multisystemic nature of fatal disease in this group. The high incidence of acute renal failure in adults may be important, as shown here by the inverse relationship between creatinine levels and congestion, but requires further investigation.

Our findings emphasize the importance of cerebral microvascular obstruction in contributing to coma during severe malarial in humans. They confirm the association between sequestration of malaria-infected erythrocytes and show, for the first time to our knowledge, a strong association between coma, sequestration, and inappropriate microvascular congestion in human CM.

#### Notes

*Financial support.* This work was supported by the Wellcome Trust of Great Britain; the NIHR Biomedical Research Centre Programme, Oxford; The John Fell Fund of Oxford University; and the Thrasher Research Fund, USA (grant number 02827-2).

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

#### References

- Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 2000; 94(Suppl 1):S1–90.
- Newton CR, Taylor TE, Whitten RO. Pathophysiology of fatal falciparum malaria in African children. Am J Trop Med Hyg 1998; 58: 673–83.
- Carter JA, Mung'ala-Odera V, Neville BG, et al. Persistent neurocognitive impairments associated with severe falciparum malaria in Kenyan children. J Neurol Neurosurg Psychiatry 2005; 76:476–81.
- 4. John CC, Bangirana P, Byarugaba J, et al. Cerebral malaria in children is associated with long-term cognitive impairment. Pediatrics **2008**; 122:e92–9.
- 5. Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev **2004**; (2):CD000363.
- 6. White NJ. The role of anti-malarial drugs in eliminating malaria. Malar J **2008**; 7(Suppl 1):S8.
- MacPherson GG, Warrell MJ, White NJ, Looareesuwan S, Warrell DA. Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol 1985; 119:385–401.
- Pongponratn E, Riganti M, Punpoowong B, Aikawa M. Microvascular sequestration of parasitized erythrocytes in human falciparum malaria: a pathological study. Am J Trop Med Hyg **1991**; 44:168–75.
- Silamut K, Phu NH, Whitty C, et al. A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Pathol 1999; 155:395–403.
- Pongponratn E, Turner GD, Day NP, et al. An ultrastructural study of the brain in fatal *Plasmodium falciparum* malaria. Am J Trop Med Hyg 2003; 69:345–59.
- Taylor TE, Fu WJ, Carr RA, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med 2004; 10: 143–5.
- Kraemer SM, Smith JD. A family affair: var genes, PfEMP1 binding, and malaria disease. Curr Opin Microbiol 2006; 9:374–80.
- Chakravorty SJ, Craig A. The role of ICAM-1 in *Plasmodium falciparum* cytoadherence. Eur J Cell Biol 2005; 84:15–27.
- 14. White NJ, Turner GD, Medana IM, Dondorp AM, Day NP. The murine cerebral malaria phenomenon. Trends Parasitol **2010**; 26:11–15.
- de Souza JB, Hafalla JC, Riley EM, Couper KN. Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease. Parasitology **2010**; 137:755–72.
- Tripathi AK, Sha W, Shulaev V, Stins MF, Sullivan DJ. *Plasmodium falciparum*-infected erythrocytes induce NF-kappaB regulated in-flammatory pathways in human cerebral endothelium. Blood 2009; 114:4243–52.
- 17. Jambou R, Combes V, Jambou MJ, et al. *Plasmodium falciparum* adhesion on human brain microvascular endothelial cells involves transmigration-like cup formation and induces opening of intercellular junctions. PLoS Pathog **2010**; 6:e1001021.
- Medana IM, Turner GD. Human cerebral malaria and the blood-brain barrier. Int J Parasitol 2006; 36:555–68.
- Rowe JA, Claessens A, Corrigan RA, Arman M. Adhesion of *Plasmodium falciparum*-infected erythrocytes to human cells: molecular mechanisms and therapeutic implications. Expert Rev Mol Med **2009**; 11:e16.
- Rogerson SJ, Grau GE, Hunt NH. The microcirculation in severe malaria. Microcirculation 2004; 11:559–76.
- Dondorp AM, Pongponratn E, White NJ. Reduced microcirculatory flow in severe falciparum malaria: pathophysiology and electronmicroscopic pathology. Acta Trop 2004; 89:309–17.
- 22. Looareesuwan S, Wilairatana P, Krishna S, et al. Magnetic resonance imaging of the brain in patients with cerebral malaria. Clin Infect Dis **1995**; 21:300–9.

Downloaded from http://jid.oxfordjournals.org/ at Washington University School of Medicine Library on August 29, 2012

- Tran TH, Day NP, Nguyen HP, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335:76–83.
- 24. Medana IM, Day NP, Hien TT, et al. Axonal injury in cerebral malaria. Am J Pathol **2002**; 160:655–66.
- Parums DV, Cordell JL, Micklem K, et al. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 1990; 43:752–7.
- Erber WN, McLachlan J, Cordell JL, et al. A new monoclonal antibody (JC159) that detects glycophorin A for the diagnosis of erythroleukaemia. Hematol Rev 1991; 5:113–20.
- Lu M, Zhang ZG, Chopp M. Analysis of cerebral microvascular architecture—application to cortical and subcortical vessels in rat brain. J Neurosci Methods 2004; 138:81–7.
- Lauwers F, Cassot F, Lauwers-Cances V, Puwanarajah P, Duvernoy H. Morphometry of the human cerebral cortex microcirculation: general characteristics and space-related profiles. Neuroimage 2008; 39: 936–48.
- Marchiafava E, Bignami A. "On summer-autumnal malaria fever." In: Malaria and the parasites of malaria fevers. Vol 150. London: The New Sydenham Society, 1894:1–234.
- Newton CR, Hien TT, White N. Cerebral malaria. J Neurol Neurosurg Psychiatry 2000; 69:433–41.
- Milner DA Jr. Rethinking cerebral malaria pathology. Curr Opin Infect Dis 2010; 23:456–63.

- 32. Clark IA, Cowden WB. The pathophysiology of falciparum malaria. Pharmacol Ther **2003**; 99:221–60.
- Grau GE, Mackenzie CD, Carr RA, et al. Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria. J Infect Dis 2003; 187:461–6.
- Day NP, Phu NH, Mai NT, et al. The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Crit Care Med 2000; 28:1833–40.
- Medana IM, Day NP, Sachanonta N, et al. Coma in fatal adult human malaria is not caused by cerebral oedema. Malaria J 2011; 10:267.
- Kawai S, Sugiyama M. Imaging analysis of the brain in a primate model of cerebral malaria. Acta Trop 2010; 114:152–6.
- Ellis CG, Jagger J, Sharpe M. The microcirculation as a functional system. Crit Care 2005; 9(Suppl 4):S3–8.
- Dondorp AM, Ince C, Charunwatthana P, et al. Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. J Infect Dis 2008; 197:79–84.
- 39. Dondorp A, Nosten F, Stepniewska K, Day N, White N. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366:717–25.
- 40. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet **2010**; 376:1647–57.